• Inicio
• Patronato
• Comité Internacional
• Congresos
• Publicaciones
• Investigación y Docencia
• Contactar

Congresos

International Meeting on Strategies for Studying CNS: Active Compounds: Models, Screens and Clinical Syndromes

Madrid

April 26 - May 2 1992

The content of this congress, together with other contributions on the topic, are collected in vol. 1 and 2 of the series "Strategies for studying brain disorders".

PROGRAMME

1. S1. ANIMAL MODELS AND DRUG SCREENS IN ANTIDEPRESSANT RESEARCH
   • G. Kenneth Lloyd, UK. GABAergic antidepressants
   • Steven F. Maier, USA. Models based on a learned helplessness hypothesis
   • Gerard Marek, USA. The DRL antidepressant screen
   • Gerald Curzon, UK. Freeding models relating to 5-HT agonista and antagonist
   • Paul Willner, UK. Stress and conflict: Behavioural symptoms related to depression
   • H. Christian Fibiger, Canada. Neuropharmacology of depresión
2. S2. CLINICAL ETIOLOGY AND TREATMENT IN RELATION TO SEP, FEEDING AND DEPRESIÓN
   • Sara Leibowitz, USA. Feeding disorders and depresión
   • Alfred Lewy, USA. Biological rhythms and depresión
   • Rutger van den Hoofdakker, The Netherlands. Antidepressant effects of sleep deprivation
   • PhilipW. Gold, USA. Neuroendocrinology of depression
   • F. Borsini, Italy. Behavioural despair syndrome
   • G. M. Goodwin, UK. SPECT and its use in depression
3. S3. Drug effects on social behaviour, aggression and anxiety
   • Berend Olivier, The Netherlands. Drugs, neurotrasmitters and offensive aggression
   • David Sanger, France. Suppression of social behavoiour and conditioned performance
   • Barry Everitt, USA. Motivation and performance in male sexual behaviour
   • Tom Insel, USA. Neuropeptides and maternal separation distress
   • J. Barret, USA. Anxiolytics
   • R. J. Blanchard, USA. Fear-defensive reactions
4. S4. Clinical etiology and treatment in relation to sex and aggression, depression and anxiety
   • Markuu Linnoila, USA. 5-HT and affective disorders
   • Donald Charney, USA. Serotonin anxiety and deppession
   • Charles Nemeroff, USA. Peptides: Affective disorders
   • J.F. William Deakin, UK. The 5-HT receptor imbalance theory of affective disturbance: Experimental test in humans
   • Athanatios Zis, Canada. On the mechanism of actino of E.C.T.: Neuroendocrine and brain microdialysis studies
   • E. de Souza, USA. Role of corticotropin-releasing factor in neuropsychiatric disorders
   • Joaquin del Rio, Spain. The posible role of serotonin receptor subtypes in psychiatric syndromes
5. S5. Opiates and psychostimulants
   • Robert Blaster, USA. Evaluation of pharmacoterapies for drug abuse treatment: Animals studies
   • Christina Spyraki, Greece. Neural basis of drug reinforcement
   • George Ricaute, USA. Substituted phenethylamine toxicity in animals and humans
   • John Woods, USA. Opiates
   • John Hughes, UK. Opiate receptors
   • Paolo Nencini, Italy. Interactions between opioids and stimulants
6. S6. Alcohol use and abuse
   • Charles O’Brien, USA. Efficacy of treatment of alcoholism
   • John Littleton, UK. Calcium antagonist and alcohol withdrawal
   • Boris Tabakoff, USA. Biochemical mechanisms of tolerance
   • Michael Shuckit, USA. Genetic studies of alcoholism
   • Edward Sellers, Canada. Serotonergic compounds in the treatment of alcoholism
   • E. Hárd, Sweden. Neonatal alcohol syndrome
7. S7. Abuse potencial of CNS drugs used therapeutically
   • Linda Dykstra, USA. CNS side effects of opiates
   • J. David Leander, USA. PCP-like NMDA antagonists: Clinical effects.
   • Cristina E. Johanson, USA. CNS side effects of benzodiazepines
   • Malcolm Lader, UK. Dependence aspects of anxiolytic drugs
   • Miguel Casas, Spain. Relevance of Dopamine systems in chemical addictions
8. S8. Animal models and drug screens in antipsychotic research
   • Sven Ahlenius, Sweden. Animal models and the evaluation of antipsychotic drugs
   • Brenda Costall, UK. Models of schizopsychotic disorders
   • Torgny H. Svensson, Sweden. Electrophysiology in the development of screens
   • Francis Colpaert, France. New concepts in the development of antipsychotic drugs
   • Lennart Heimer, USA. Perspectives on basal forebrain organization and psychotic disorders
   • L Creese, USA. DA receptors and drug action
9. S9. Clinical research into new antipsychotic drugs considering long-term therapeutic benefits and EPS
   • Tommy Lewander, Sweden. Remoxipride: Clinical profile
   • G. Sedwall, Sweden. PET scanning: D2 receptors and psychosis
   • R. Meibach, USA. Risperidone: Clinical profile
   • F. Kleinman, USA.The neuropathology of schizophrenia
   • T. G. Heffner, USA. New views on antipsychotic drugs
   • R. E. Pyke, USA. Thiosperone (BMY 1486): Clinical Results
   • Arvid Carlsson, Sweden. General aspects on the action of neuroleptic drugs
10. S10. Toxins that cause dísorders in animals
    • Irwin Kopin, USA. MPTP and neurodegeneration
    • M. Morelli, Italy. Priming of DA receptor supersensitivity
    • Alan R Crossman, UK. Excitatory amino acids in movement disorders
    • Justo García-Yébenes, Spain. Effects of growth factors on catecholamine cells
    • E. D. Abercombie, USA. Toxins that cause disorders in animals
    • Patrick McGeer, Canadá. Neurotransmitter turnover and endotoxic cell damage
    • R. Schwarcz, USA. Endogenous excitotoxins in neurodegenerative brain diseases
11. S11. Etiology and treatment of movement disorders such as Parkinson's dísease, Hungtingtons chorea and epilepsy
    • 0leh Hornykiewicz, Austria. Aging and cellular mechanisms of basal ganglia diseases
    • Sten-Magnus Aquilonius, Sweden. Parkinson's disease
    • Giuseppe Bartholini, France. Basal ganglia mechanisms involved in movement disorders
    • P. Groves, USA. Nigral striatal system in motor dysfunction
    • P. R Sanberg, USA. Huntington's chorea and cognitive disorders
    • A. Portera-Sánchez, Spain. Epidemiology and Etiology of parkisonism
12. S12. Brain mechanisms of learning processes and the assessment of efficacy of cognition enhancers
    • D. Price, USA. Non-human primates and trophic factors
    • John Harvey, USA. Effects of drugs on classical conditioning
    • D. Stephens, Germany. Benzodiazepines, O-carbolines and learning
    • D. Olton, USA. Theories of learning related to long-term and short-term memory
    • Ivan Izquierdo, Brazil. Brain BZ/GABA - A modulation of memory
    • N. White, Canada. Brain mechanisms in the assessment of cognitive enhancers
    • L. Cook, USA. Preclinical aspects of cognition enhancers
13. S13. Human syndromes which have as theír symptom the dísruption of memory and learning
    • José Luis López-Ibor, Spain. Current classification of Dementia
    • F. Growden, USA. Clinical features of Alzheimer's disease
    • M. J. de León, USA. Imaging analysis in Alzheimer's disease
    • B. Cordell, USA. Amyloidogenesis in Alzheimer’s disease
    • E. K Warlington, UK. Semantic memory deficit in progressive degenerative disease
    • T. Douka, Germany. Clinical aspects of cognition enhancers
    • Vicky Chan-Palay, Switzerland. Depression and Dementia: Therapeutic strategies

STRATEGIES FOR STUDYING BRAIN DISORDERS

Inscrita en el registro de fundaciones docentes y de investigación, MAD-1-3-601

© 2009 Fundación Cerebro y Mente Todos los derechos reservados